目的 研究经后路椎体间植骨融合术治疗老年退变性腰椎滑脱合并腰椎管狭窄症的临床效果。方法 将我院110例老年退变性腰椎滑脱合并腰椎管狭窄症患者抽签分为研究组与对照组,两组均为55例,研究组采取经后路椎体间植骨融合术治疗,对照组采取传统手术治疗,比较两组临床效果、Prolo评分及术中出血量、术后引流量、术后卧床时间及手术时间差异。结果 研究组总有效率与对照组总有效率分别为90.91%、92.73%,比较无统计学意义(P＞0.05);术后研究组Prolo功能、症状、总分均高于对照组(P＜0.05),滑移率比较无统计学意义(P＞0.05);研究组术中出血、术后引流量及术后卧床时间低于对照组(P＜0.05),手术时间比较无统计学意义(P＞0.05)。结论 经后路椎体间植骨融合术治疗老年退变性腰椎滑脱合并腰椎管狭窄症疗效确切,短期效果与传统术式相似,但可加快患者功能恢复,降低手术过强应激反应,具有较高的临床价值。

目的 探讨DPP-4抑制剂联合二甲双胍治疗2型糖尿病的临床疗效及安全性。方法 选取医院近3年收治的糖尿病病人70例,随机分为对照组(35例)和治疗组(35例),对照组给予二甲双胍治疗,治疗组给予二甲双胍联合DPP-4抑制剂控制血糖,经3个月治疗,比较治疗后血糖指标、胰岛功能指标及低血糖、不良反应情况。结果 对照组和治疗组治疗后FPG、2hPG、HbA1c水平均有降低,治疗组治疗后血糖检测指标优于对照组(P＞0.05)。胰岛功能监测显示治疗组治疗后空腹胰岛素、服糖后2小时胰岛素浓度升高优于对照组,胰高血糖素水平降低幅度大于对照组,治疗前后胰岛素及胰高血糖素均有变化,组间比较P＞0.05,有临床意义。治疗期间两组患者均未发生低血糖、药物不良反应。结论 DPP-4抑制剂联合二甲双胍可显著提高降糖效果,改善胰岛功能,并且无低血糖、药物不良反应发生。

目的 了解近5年来阴沟肠杆菌在我院的临床分布及耐药性的变迁情况。方法 采用K-B纸片法进行药物敏感性测定,再用双纸片法检测超广普β-内酰胺酶(ESBLs)。结果 2010年1月—2014年12月我院共分离阴沟肠杆菌261株,其中2010年分离48株(18.4%)、2011年50株(19.2%)、2012年52株(19.9%)、2013年54株(20.7%)、2014年57株(21.2株%);主要分布于重症监护室(ICU)、呼吸内科、肝胆外科,分别占49.%(130株)、14.9%(39株)、11.9%(31株),标本来源主要为痰液、尿液及伤口分泌物,分别占52%、13.5%、12.8%,ESBLs菌株的检出率为29.9%(78株),产酶株的耐药性高于非产酶株,全部菌株对亚胺培南敏感。结论 阴沟肠杆菌主要引起呼吸道、尿路和各种伤口感染,多发于ICU患者,并且呈逐年增多趋势,产ESBLs在阴沟肠杆菌中广为流行,合理使用抗菌药物(尤其是第三代头孢菌素)是减少产ESBLs株流行的重要措施。

Objective To investigate the clinical distribution and antimicrobial resistance of infections caused by enterobacter cloacae in our hospital. Methods Antimicrobial susceptibility tests were done by Kirby-Bauer disk diffusion method. The extended-spectrum β-Lactamases (ESLBS) were detected by double disc diffusion test. Results A total of 261 strains of E cloacae were isolated from Jan 2010 to Dec 2014. The percentages of these strains isolated in 2010, 2011, 2012, 2013, 2014 were 18.4%, 19.2%, 19.9%, 20.7%, 21.2% respectively. E cloacae were mainly isolated from intensive care unit (ICU) (49.0%), respiratory medicine (14.9%) and surgery (11.9%) respectively. The percentages of these strains isolated from sputum, urine and wound secretion were 52.0% 13.5% and 12.8% respectively. The percentages of ESBLS producer was 29.9% (78 strains).Their resistance was obviously higher than that of non-ESBLS producer. But all strain were sensitive to imipenem. Conclusion E Cloacae caused infections of respiratory tract, urinary and wound principally in clinic. The most of which occured in ICU. The ESBLS are popular in E cloacae and show the increasing trend year by year. The restricted use of antimicrobial drug is a considerable measure which reduces prevalence of ESBLS producing strains.

目的 回顾性分析采用内镜下氩离子凝固术治疗胃出血的治疗效果,为临床治疗胃出血提供经验及理论基础。方法 选取2010年1月—2014年7月我院收治的胃出血患者199例,随机分为两组,分别对其进行内镜下氩离子凝固术治疗和内镜下高频电凝治疗,总结对比其治疗效果,并对其并发症情况进行统计。结果 经治疗后,A组28例胃黏膜溃烂出血患者未再出血27例(96.43%),E组22例胃黏膜溃烂出血患者未再出血例数17例(77.27%),差异有统计学意义(P<0.05);A组治疗后形成局部炎性肉芽肿及发生胃穿孔的百分比低于E组,差异有统计学意义(P<0.05)。结论 采用内镜下氩离子凝固术治疗胃出血,止血率高,并发症发生率低,效果良好,值得在临床中推广使用。

Objective A retrospective analysis was performed using endoscopic argon plasma coagulation treatment of stomach bleeding, to provide experience and theoretical basis for the clinical treatment of stomach bleeding. Methods January 2010-July 2014 199 cases of bleeding in patients admitted to our hospital.They were randomly divided into two groups and had therapeutic endoscopic argon plasma coagulation. We summarized the treatment effect and its complications statistics. Results After therapy, 27 gastric mucosa fester patients(96.43%) of 28 patients in group A stopped bleeding and 17 gastric mucosa fester patients(77.27%) of 22 patients in group B stopped bleeding and the difference is statistical significance(P<0.05), and the incidence rate of inflammatory granuloma and gastric perforation of group A is significant lower than that of group B (P<0.05). Conclusion Endoscopic argon plasma coagulation therapy is taken to treat gastrorrhagia, hemostasis rate is higher and complication rate is lower. It is worth widely using in the clinic.

目的 对兰索拉唑肠溶片联合氟哌噻吨美利曲辛治疗焦虑糜烂性胃炎患者的治疗效果进行研究。方法 选取2013年1月—2015年1月在我院收治的伴有焦虑情绪的糜烂性胃炎患者106例。随机分为对照组,给予兰索拉唑肠溶片治疗,观察组,给予兰索拉唑肠溶片联合氟哌噻吨美利曲辛治疗,并且对疗效进行比较。结果 治疗前,两组患者在腹痛、腹胀、反酸、嗳气以及黏膜糜烂各指标评分比较,差异无统计学意义(P>0.05);治疗后,2组患者以上指标均有所改善,并且观察组患者同期指标改善均优于对照组(P<0.05);治疗前,两组患者胃黏膜中PGE2和MDA含量无差异(P>0.05);治疗后,两组患者的PGE2均上升,而MDA则下降,并且观察组患者PGE2含量比对照组高,MDA则比对照组低,差异均有统计学意义(P<0.05);治疗前,两组患者HAMA、HAMD评分差异不明显,无统计学意义(P>0.05);治疗后,两组患者焦虑情况均有所改善,并且观察组患者情绪改善程度优于对照组患者,差异均有统计学意义(P<0.05);观察组不良反应发生率为5.6%,对照组不良反应发生率5.6%,差异无统计学意义,P>0.05。结论 兰索拉唑与氟哌噻吨美利曲辛联合应用有助于改善糜烂性胃炎患者的病情,并且可以缓解患者的焦虑情绪,安全性高,值得临床推广。

Objective To observe the clinical efficacy of lansoprazole enteric-coated tablets combined with flupentixol-melitracen in treating anxiety patients with erosive gastritis. Methods 106 patients with erosive gastritis and anxiety in our hospital from January 2013 to January 2015 were divided into an observation group and a control group, with 53 patients in each group. The control group was given lansoprazole enteric-coated tablets alone, and the observation group was treated with lansoprazole enteric-coated tablets and flupentixol-melitracen. Clinical symptoms and mucosal erosion were compared between the two groups of patients before and after treatment. Gastric mucosa malondialdehyde (MDA) and prostration E2 (PGE2) contents, anxiety and depression status were also assessed. Results After treatment, the scores of abdominal pain, bloating, acid reflux, belching, and mucosal erosions were significantly lower in the observation group than in the control group (P< 0.05). PGE2and MDA contents in the gastric mucosa in the observation group were different from those in the control group(P< 0.05). HAMA and HAMD scores were lower in the observation group than in the control group (P< 0.05). There was no difference of adverse reaction rate between the control group and the observation group (P>0.05). Conclusion Lansoprazole enteric-coated tablets combined with flupentixol-melitracen has better clinical efficacy than lansoprazole enteric-coated tablets only in patients with erosive gastritis and anxiety in terms of the improvement of clinical symptoms and mucosal erosion and the relief of negative emotions.

目的 探讨纵隔髓外造血(EMH)的临床特点,从而为其诊断、治疗提供参考意见。方法 总结分析我科收治的1例双侧后纵隔骨髓外造血组织多发瘤样增生,并对近10年来国内相关文献报道的27例病例进行回顾性分析。结果 患者需行手术活检取得病理诊断,确诊髓外造血。结论 纵隔髓外造血瘤样增生是一种罕见特殊的良性病变, 预后良好。但因其临床表现和影像学均缺乏特异性,当临床中遇到发生在后纵隔脊柱旁的占位性病变,同时患有贫血的患者应考虑EMH 的可能性,给予经皮穿刺或者胸腔镜下活检来取得细胞学诊断,从而避免不必要的手术治疗。

Objective To probe into the clinical features of mediastinal extramedullary hematopoiesis (EMH), for providing a reference for clinical diagnosis and treatment. Methods The clinical data was studied in a case of mediastinal EMH from our department, and 27 case reports from domestic published literatures over the last decade were analyzed retrospectively. Results Of the 27 patients, 15 received surgical excision, while the other 12 underwent needle biopsy. In our patient, the diagnosis of EMH was made by mini thoracotomy and open biopsy. Conclusion Mediastinal EMH is a rare disease and its prognosis is well. Because there is no obvious specific clinical symptoms and imaging appearances, the possibility of EMH should be considered when a patient with a mediastinal tumor associated with anemia is encountered. Diagnosis can be achieved by needle biopsy or video-assisted thoracic surgery (VATS) in order to prevent unnecessary surgical procedures.

目的 探讨子宫内膜微腺体癌的临床病理特征、诊断及鉴别诊断。方法 对1例首诊误诊为子宫颈微腺体增生的子宫内膜微腺体癌病例进行临床、病理组织学及免疫组织化学特征的观察及总结,同时进行相关文献复习。结果 本例患者年龄61岁,因绝经后阴道不规则流血1年就诊,B超提示子宫内膜不规则增厚,并行分段诊刮术,先后两次诊刮标本光镜下均见黏液性柱状上皮呈乳头状及网格状结构,细胞轻度异型,核分裂罕见,间质内大量中性粒细胞浸润伴腺上皮内“微脓肿”形成;免疫组化示:上皮成分P16弥漫强(+),CEA小灶(+),Vimentin弥漫(+),ER约90%(+,中-强),PR约90%(+,弱),Ki-67约3%(+),间质细胞CD10(+)、CD34(-)。结论 子宫内膜微腺体癌是一种极为罕见的子宫内膜黏液腺癌,其组织学形态与子宫颈良性病变微腺体增生十分相似,易于混淆,但通过免疫组化检查及详细地临床病史资料收集、分析,可以与其鉴别,从而做出正确地诊断。

Objective To investigate clinical and histopathological features, dignosis and differential diagnosis of the endometrial microglandular adenocarinoma (MGA). Methods The clinical and pathological features of microglandular adenocarinoma in a patient were observed. Immunohistochemical staining and literature review were also used. Results In the case, the age of patient was 61 years. Clinical manifestation was vaginal irregular bleeding for 1 year. Type-B ultrasound suggested endometrium was irregular thickening. Histologically, it was mainly composed of irregular shape, closely spaced small glands, and glandular cells was mild atypical. Mitosis was rarely observed. The endometrial stromata between gland were rare, but neutrophil were much observed with the formation of neutrophil microabscess in the glandular epithelium. Immunohistochemical study showed neoplastic cells were diffuse and strongly positivity for P16, diffuse positivity for vimentin, focally positive for CEA. ER and PR expression was found in approximately 90% tumor cells. The index of Ki-67 was about 3%. Interstitial cells were positivity for CD10, negativity for CD34. Conclusion The microglandular adenocarcinoma is a rare endometrial adenocarcinoma. It can be differentiated from cervical microglandular hyperplasia(MGH) and cervical mucinous adenocarcinoma by immunohistochemistry and morphological characteristics.

目的 评估重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白（rhTNRF：Fc）治疗难治性慢性痛风性关节炎的临床疗效及安全性。方法 选取2022年1月一2023年12月广州中医药大学顺德医院风湿科门诊收治的46例难治性痛风性关节炎患者,分为观察组和对照组两组,对照组规范使用降尿酸药物治疗,观察组在对照组治疗的基础上联合使用rhTNRF：Fc至少12周,在0、12、24、48周观察两组的血尿酸（sUA）、肿瘤坏死因子-α（TNF-α）、关节肌肉骨骼超声变化、痛风发作例数、肝肾功能等指标。结果 观察组与对照组sUA无明显差别（P>0.05）,TNF-α水平明显下降（P<0.05）,滑膜炎、关节积液影像表现减少（P<0.05）,痛风发作例数明显减少（P<0.05）,观察期间肝肾功能正常,无患者因不良反应退出研究。结论 rhTNRF：Fc对难治性慢性痛风性关节炎安全有效。

Objective To explore the efficacy and safety of recombinant human type II tumor necrosis factor receptor-antibody fusion protein（rhTNRF：Fc）in refractory chronic gouty arthritis. Methods From January 2022 to December 2023, 46 cases of refractory chronic gouty arthritis in the Rheumatology Outpatient Department,Shunde Hospital Guangzhou University of Chinese Medicine were selected and divided into an observation group and a control group. The control group received routine treatment,while the observation group received rhTNRF：Fc treatment additionally for at least 12 weeks, two groups of indicators such as serum urine acid（sUA）, TNF-α, changes in musculoskeletal ultrasound,number of gout attacks,hepatic and renal function at 0, 12, 24, and 48 weeks were observed. Results There was no significant difference in sUA between the observation group and the control group（P>0. 05）, TNF-α significantly decreased（P<0. 05）, synovitis and joint effusion imaging manifestations reduced（P<0. 05）, number of gout attacks decreased（P<0. 05）. During the observation period, liver and kidney function were normal, and no patients withdrew from the study due to adverse reactions. Conclusions Using rhTNRF：Fc is safe and effective in treating refractory chronic gouty arthritis.

        目的   明确输血前各抗体的分布特点，探讨自身抗体和同种抗体在性别、年龄、输血史、妊娠史和不同疾病中的差异，并根据抗体血型血清学特性制定个体输血方案，以确保临床输血安全。方法    选取2021年6月—2024年8月在广东省第二人民医院输血科申请输注红细胞或手术备血的29 662例患者，采用低离子抗人球蛋白微柱凝胶法进行不规则抗体筛查，结果阳性的标本经科内讨论并送广州血液中心血型参比实验室进行抗体鉴定，通过统计血液中心回报结果分析各抗体的特异性。结果  29 662例患者标本中不规则抗体结果为阳性的有208例，阳性率为0.70%。同种抗体占比47.69%，Rh、MNS和Lewis红细胞血型系统共占同种抗体中的94.50%，其中常见意外抗体：抗-E占31.87%、抗-M占14.29%、抗-Mur占19.78%、抗-C占7.69%和抗-e占7.69%。同种抗体与自身抗体在性别、年龄、妊娠史等方面比较差异无统计学意义（P＞0.05）；在输血史及不同科室疾病等方面比较差异有统计学意义（P＜0.05）。结论    输血前进行输血相容性检测是必要的，应对拟申请红细胞的患者进行不规则抗体筛查，阳性者宜进行抗体鉴定，明确其抗体的特异性及临床意义，以确保临床输血安全。

       Objective  To clarify the distribution characteristics of each antibody before transfusion，to explore the differences between autoantibodies and homologous antibodies in gender，age，history of blood transfusion，history of pregnancy and different diseases，and to formulate individual transfusion protocols based on the serological characteristics of antibody blood groups to ensure the safety of clinical blood transfusion．Methods  A total of 29 662 patients who applied for red blood cell transfusion or surgical blood preparation in the hospital from June 2021 to August 2024 were selected for irregular antibody screening by low-ion anti-human globulin microcolumn gel method．The samples with positive results were discussed within the department and sent to the Blood Type Reference Laboratory of Guangzhou Blood Center for antibody identification．The specificity of each antibody was analyzed by blood center reported results．Results  Among 29 662 patients，208 were positive for irregular antibody，the positive  rate was 0.70%．The alloantibodies accounted for 47.69%，Rh，MNS and Lewis erythrocyte blood group system accounted for 94.50% of alloantibodies，among which the common unexpected antibodies were anti-E 31.87%，anti-M 14.29%，anti-MUR 19.78%，anti-C 7.69% and anti-E 7.69%．There were no significant differences between alloantibodies and autoantibodies in gender，age and pregnancy history（P＞0.05）．There were statistically significant differences in blood transfusion history and diseases in different departments（P＜0.05）．Conclusions  It is necessary to test the compatibility of blood transfusion before transfusion．Screening for irregular antibodies should be carried out in prospective transfusion patients，and antibody identification should be carried out in positive patients to clarify the specificity and clinical significance of their antibodies to ensure the safety of clinical transfusion．

       糖尿病肾病（DN）是指由糖尿病所致的慢性肾脏疾病，是目前我国和全球范围内慢性肾脏疾病和终末期肾脏疾病的首位病因。DN发病率逐年攀升，且预后不良，已成为我国重大的公共卫生问题之一。DN不仅明显降低了患者的生活质量，还增加了心血管疾病的风险。随着对DN发病机制的深入研究，近十余年来在DN治疗手段方面取得了显著进展，包括新型药物的研发、生活方式的干预及各种新兴疗法的探索。本文旨在系统性综述近年来DN领域的重要治疗进展，阐明这些进展在临床应用中的有效性和适用性，并展望未来的研究方向，以期为临床实践提供参考和指导。

       Diabetic nephropathy（DN）is a form of chronic kidney disease（CKD）induced by diabetes．Diabetic nephropathy represents the leading cause of CKD and end-stage renal disease both in China and globally．The incidence of DN has been steadily increasing and its prognosis remains unfavorable．Diabetic nephropathy has become a major public health concern．Diabetic nephropathy not only significantly affects patients’ quality of life but also increases the risk of cardiovascular diseases．Recent advancements in our understanding of the pathogenesis of DN have facilitated significant progress in treatment options over the past decade．These developments include the introduction of novel pharmacological agents，the implementation of lifestyle modifications，and the exploration of various emerging therapeutic approaches．This  review aims to  systematically expound the significant therapeutic advancements in the field of DN in recent years，evaluate the efficacy and applicability of these advancements in clinical practice，and explore potential future research directions，thereby providing valuable insights andguidance for clinical practice．